Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

United Arab Emirates Officials Check Korea's Healthcare Infrastructure To Support Medical Tourism MOU

This article was originally published in PharmAsia News

Executive Summary

SEOUL - In a follow-up to a memorandum of understanding signed in March to draw medical tourists to South Korea, feasibility study officials from the Ministry of Health of the United Arab Emirates and Abu Dhabi Health Authority visited Korea June 26-30

You may also be interested in...



South Korea Hopes To Remove Hospital Legal Hurdles To Draw More Medical Tourism Patients

The government is striving to eradicate regulations banning hospitals from opening and operating their own medical hotels where foreign patients and their families can stay during treatment.

In Medical Tourism Drive, Korea's JW Choongwae Links Up With Kazakhstan's JSC Chempharm To Build Manufacturing Plant

SEOUL - Korea's sixth-largest pharma JW Choongwae Pharmaceutical Corp. has signed a memorandum of understanding with Kazakhstan's JSC Chempharm to build a manufacturing plant in Kazakhstan on a turn-key basis

In Medical Tourism Drive, Korea's JW Choongwae Links Up With Kazakhstan's JSC Chempharm To Build Manufacturing Plant

SEOUL - Korea's sixth-largest pharma JW Choongwae Pharmaceutical Corp. has signed a memorandum of understanding with Kazakhstan's JSC Chempharm to build a manufacturing plant in Kazakhstan on a turn-key basis

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC078555

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel